Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe PARP Inhibitor Biomarkers Market, by Product
1.4.2 Europe PARP Inhibitor Biomarkers Market, by Application
1.4.3 Europe PARP Inhibitor Biomarkers Market, by Services
1.4.4 Europe PARP Inhibitor Biomarkers Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Europe PARP Inhibitor Biomarkers Market by Product
4.1 Europe Kits Market by Country
4.2 Europe Assays Market by Country
Chapter 5. Europe PARP Inhibitor Biomarkers Market by Application
5.1 Europe Breast Cancer Market by Country
5.2 Europe Ovarian Cancer Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe PARP Inhibitor Biomarkers Market by Services
6.1 Europe BRCA 1 & 2 Testing Market by Country
6.2 Europe HRD Testing Market by Country
6.3 Europe HRR Testing Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe PARP Inhibitor Biomarkers Market by Country
7.1 Germany PARP Inhibitor Biomarkers Market
7.1.1 Germany PARP Inhibitor Biomarkers Market by Product
7.1.2 Germany PARP Inhibitor Biomarkers Market by Application
7.1.3 Germany PARP Inhibitor Biomarkers Market by Services
7.2 UK PARP Inhibitor Biomarkers Market
7.2.1 UK PARP Inhibitor Biomarkers Market by Product
7.2.2 UK PARP Inhibitor Biomarkers Market by Application
7.2.3 UK PARP Inhibitor Biomarkers Market by Services
7.3 France PARP Inhibitor Biomarkers Market
7.3.1 France PARP Inhibitor Biomarkers Market by Product
7.3.2 France PARP Inhibitor Biomarkers Market by Application
7.3.3 France PARP Inhibitor Biomarkers Market by Services
7.4 Russia PARP Inhibitor Biomarkers Market
7.4.1 Russia PARP Inhibitor Biomarkers Market by Product
7.4.2 Russia PARP Inhibitor Biomarkers Market by Application
7.4.3 Russia PARP Inhibitor Biomarkers Market by Services
7.5 Spain PARP Inhibitor Biomarkers Market
7.5.1 Spain PARP Inhibitor Biomarkers Market by Product
7.5.2 Spain PARP Inhibitor Biomarkers Market by Application
7.5.3 Spain PARP Inhibitor Biomarkers Market by Services
7.6 Italy PARP Inhibitor Biomarkers Market
7.6.1 Italy PARP Inhibitor Biomarkers Market by Product
7.6.2 Italy PARP Inhibitor Biomarkers Market by Application
7.6.3 Italy PARP Inhibitor Biomarkers Market by Services
7.7 Rest of Europe PARP Inhibitor Biomarkers Market
7.7.1 Rest of Europe PARP Inhibitor Biomarkers Market by Product
7.7.2 Rest of Europe PARP Inhibitor Biomarkers Market by Application
7.7.3 Rest of Europe PARP Inhibitor Biomarkers Market by Services
Chapter 8. Company Profiles
8.1 Myriad Genetics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.2 Thermo Fisher Scientific, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 SWOT Analysis
8.3 Illumina, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segment and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Neogenomics, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 Qiagen N.V.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Agilent Technologies, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Merck KGaA
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 AstraZeneca PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis